Attempts at chemotherapy of Echinococcus multilocularis infections in rodents. II. A study of some parasiticides and cytostatic agents

1971 ◽  
Vol 49 (10) ◽  
pp. 1301-1304 ◽  
Author(s):  
G. Lubinsky ◽  
Ch.-F. Lee ◽  
R. W. Baron
Keyword(s):  
Echinococcus Multilocularis ◽  
Cytostatic Agents

Seven parasiticides were studied for their ability to inhibit the growth of Echinococcus cysts, but none was found to be active. Of the six cytostatic agents examined, demecolcine and dactinomycin inhibited the growth of cysts, but only when used in toxic doses.

Acceleration of the growth of populations and of the multiplication of tetrathyridia of Mesocestoides corti Hoeppli, 1925 (Cestoda: Cyclophyllidea) by some cytostatic agents

1973 ◽  
Vol 51 (1) ◽  
pp. 83-90 ◽  
Author(s):  
Marie Novak ◽  
George Lubinsky
Keyword(s):  
Echinococcus Multilocularis ◽  
Considerable Increase ◽  
Single Injection ◽  
Total Biomass ◽  
Cytostatic Agents ◽  
Average Size

Experiments with tetrathyridia of Mesocestoides corti implanted intraperitoneally into LDF1, SEC, and SWR mice showed that a single injection of cyclophosphamide, 200 mg/kg 1 day after infection, increased the total biomass of tetrathyridial populations in mice dissected 50 days later by 50 to 200%. Similar, though less pronounced, increases in the total biomass of populations were produced by dactinomycin, 0.35 mg/kg once a week, for 4 to 6 weeks. The average size of individual tetrathyridia decreased despite a considerable increase in the total biomass of their populations.The parasiticides lucanthone, which inhibits the growth of Echinococcus multilocularis cysts, and quinacrine, which is inactive in this respect, accelerate the growth of the biomass of tetrathyridial populations much less than the cytostatic agents cyclophosphamide and dactinomycin.

The expression of TGF-β 1, TβR and Smad2/3 in liver infected with Echinococcus multilocularis

2010 ◽  
Vol 34 (8) ◽  
pp. S57-S57
Author(s):  
Jianbing Ding ◽  
Yao Li ◽  
Xu Qi ◽  
Xiumin Ma ◽  
Renyong Lin
Keyword(s):  
Echinococcus Multilocularis

In Vitro Incorporation of Sodium Acetate-l-C14 into Leukocyte Lipids of Normal and Leukaemic Subjects as a Function of Incubation Time

1962 ◽  
Vol 02 (02) ◽  
pp. 165-172
Author(s):  
C Miras ◽  
G Lewis ◽  
J Mantzos
Keyword(s):  
Sodium Acetate ◽  
Linear Part ◽  
Lipid Synthesis ◽  
Normal Subjects ◽  
Cytostatic Agents ◽  
Time Intervals ◽  
Total Blood ◽  
Effect Of Treatment ◽  
Product Relation

Summary1. Separated leukocytes or total blood from normal subjects, untreated leukaemic patients and from leukaemic patients treated with cytostatic agents were incubated with CH3COONa-l-C14. Radioactivity of mixed lipids was measured at standard time intervals.2. The time incorporation curve observed with leukocytes from treated leukaemic patients showed after an initial linear part, a more rapid levelling off than the curves observed with leukocytes from untreated and normal subjects.3. Therefore, an indirect effect of treatment on leukocyte lipid synthesis seems to be present.4. Phospholipid and neutral lipid synthesis by leukaemic leukocytes was also studied. The results give no evidence that these fractions as a whole have any precursor-product relation.

Surgical treatment of alveolar echinococcosis: a single centre experience and systematic review of the literature

2019 ◽  
Vol 98 (4) ◽  
pp. 167-173
Keyword(s):  
Case Report ◽  
Echinococcus Multilocularis ◽  
Alveolar Echinococcosis ◽  
Lymphatic System ◽  
Surgical Intervention ◽  
Clinical Symptoms ◽  
Safety Margin ◽  
Surgical Removal ◽  
Single Centre Experience ◽  
Therapeutic Procedures

Introduction: Alveolar echinococcosis (AE) is a zoonosis caused by Echinococcus multilocularis. AE is primarily localised in the liver. Echinococcus multilocularis imitates tumour-like behaviour. It can metastasise through blood or lymphatic system to distant organs. Echinococcosis often remains asymptomatic due to its long incubation period and indistinct symptoms. Clinical symptoms are determined by the parasite’s location. Diagnosis of echinococcosis is based on medical history, clinical symptoms, laboratory tests, serology results, imaging methods and final histology findings. Surgical removal of the cyst with a safety margin, followed by chemotherapy is the therapeutic method of choice. Case report: We present a case report of alveolar echinococcosis in a thirty-year-old female patient in whom we surgically removed multiple liver foci of alveolar echinococcosis. The disease recurred after two years and required another surgical intervention. Conclusions: Alveolar echinococcosis is a disease with a high potential for a complete cure provided that it is diagnosed early and that the recommended therapeutic procedures are strictly adhered to.

Dental Development in Children After Chemotherapy

2017 ◽  
Vol 68 (6) ◽  
pp. 1397-1400
Author(s):  
Cristina Bica ◽  
Mihaela Chincesan ◽  
Daniela Esian ◽  
Krisztina Martha ◽  
Valentin Ion ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Tooth Development ◽  
Lymphoblastic Leukemia ◽  
Treatment Method ◽  
Paediatric Oncology ◽  
Structural Defects ◽  
Dental Development ◽  
Cytostatic Agents ◽  
Dental Abnormalities ◽  
Tooth Buds

Chemotherapy, as a treatment method in paediatric oncology, coincides with the physiological process of tooth development. The interference between cytostatic agents and the cycle of the cells with specialised functions in the formation and mineralisation of dental structures leads to the appearance of abnormalities in the development of the tooth buds, structural defects and disorderly eruption. We have looked into the distribution of developmental tooth disorders in a group of children suffering from malignant ailments. The study reveals a high occurrence of microdontia and agenesis of premolars among children diagnosed with high-risk acute lymphoblastic leukemia at the age between 1 and 6, as well as tooth eruption disturbances in 70% of the children. The nature and the severity of dental abnormalities depend on the type of cytostatic medication, the dosage and the frequency of therapeutic cycles, the age of the child at the beginning of the oncological therapy, as well as on the stage of the odontogenesis.

ANTIBODY-DRUG CONJUGATES FOR TARGETED CANCER THERAPY

2019 ◽  
Vol 65 (6) ◽  
pp. 777-784
Author(s):  
David Korman
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Gemtuzumab Ozogamicin ◽  
Brentuximab Vedotin ◽  
Cytostatic Agent ◽  
Cytostatic Agents ◽  
Drug Conjugates ◽  
Natural Substances ◽  
Intracellular Release ◽  
High Antitumor Activity

Monoclonal antibody (MAB) conjugates with cytostatic agents (ADC) are intended for selective delivery of a cytostatic agent to a tumor cell. Three ADC have been approved for clinical use (gemtuzumab ozogamicin, brentuximab vedotin, trastuzumab-DM1); a few dozens of other ADC are undergoing clinical trials. Several derivatives of natural substances (antibiotics and inhibitors of microtubules) having a high antitumor activity are used as cytostatic agents included in ADC. They are inapplicable in clinical practice as self-sustained drugs due to their considerable toxicity. Of great importance for the implementation of the ADC effect is the character of a linker connecting MAB with a cytostatic agent and ensuring selective intracellular release after ADC internalization. The structure, mechanisms of action, and the results of clinical trials of a number of ADC are considered here as an illustration (by way of example). The development of ADC can help introduce new effective cytostatic agents into clinical practice.

Hetaryl derivatives of 7-deazapurine ribonucleosides: potent cytostatic agents

2011 ◽  
Author(s):  
Pavla Perlíková ◽  
Petr Nauš ◽  
Aurelie Bourderioux ◽  
Michal Hocek
Keyword(s):  
Cytostatic Agents ◽  
Derivatives Of
Sign in / Sign up

Export Citation Format

Share Document